|
Part A only: Participant must be at least 18 years of age at the time of signing the informed consent form (ICF) |
|
|
|
|
Part B only: Participant must be at least 12 years of age (or the minimum legal age for adolescents in the country of the investigational site) at the time of signing the ICF |
|
|
|
|
Participants must have bilateral inflammation of paranasal sinuses in CT scan with LMK ≥8 and bilateral ethmoid opacification before randomization |
|
|
|
|
Participants must have ongoing symptoms of loss of smell and rhinorrhea (anterior/posterior) of any severity, with or without facial pain/pressure for at least 12 consecutive weeks by Visit 1 |
|
|
|
|
Participants must have ongoing symptoms of nasal congestion (NC)/obstruction at least 12 consecutive weeks before Visit 1 and a NC score of ≥ 2 at Visit 1 (day score) and Visit 2 (weekly average score) |
|
|
|
|
Participants must have sTSS (NC, rhinorrhea, facial pain/pressure) ≥5 at Visit 1 (day score) and Visit 2 (weekly average score) |
|
|
|
|
Participants must have one of the 2 following features |
|
|
|
|
Prior sinonasal surgery for CRS |
|
|
|
|
Treatment with SCS therapy for CRS as defined by any dose and duration within the prior 2 years before screening (Visit 1) or intolerance/contraindication to SCS |
|
|
|
|
For Part B only: participants who have a blood eosinophil count ≥300 cells/mm3 at Screening |
|
|
|
|
Body weight ≥30 kg |
|
|
|
|
Patients with nasal conditions/concomitant nasal diseases such as nasal polyposis in endoscopy at Visit 1 or with history of nasal polyposis etc., making them non-evaluable at Visit 1 or for the primary efficacy
|
|
|
|
|
Nasal cavity malignant tumor and benign tumors
|
|
|
|
|
Forced expiratory volume (FEV1) ≤50% of predicted normal at Visit 1
|
|
|
|
|
Radiologic suspicion or confirmed invasive or expansive fungal rhinosinusitis
|
|
|
|
|
Severe concomitant illness(es) that, in the investigator's judgment, would adversely affect participation in the study
|
|
|
|
|
Active tuberculosis or non-tuberculous mycobacterial infection, or a history of incompletely treated tuberculosis unless documented adequately treated
|
|
|
|
|
Diagnosed active endoparasitic infections; suspected or high risk of endoparasitic infection
|
|
|
|
|
Known or suspected immunodeficiency
|
|
|
|
|
History of malignancy within 5 years before Visit 1, except completely treated in situ carcinoma of the cervix, and completely treated and resolved nonmetastatic squamous or basal cell carcinoma of the skin
|
|
|
|
|
Active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, or antifungals within 2 weeks before the Screening Visit 1 or during the screening period
|
|
|
|
|
History of systemic hypersensitivity or anaphylaxis to dupilumab or any of its excipients
|
|
|
|
|
Patients in prior dupilumab clinical trial or have been treated with commercially available dupilumab within 12 months or who discontinued dupilumab use due to adverse event
|
|
|
|
|
Patients who are treated with intranasal corticosteroid drops; intranasal steroid emitting devices/stents; nasal spray using exhalation delivery system, such as Xhance™, during screening period
|
|
|
|
|
Participants on unstable dose of intranasal corticosteroids (INCS) spray 4 weeks prior to Screening Visit (Visit1) and during screening period
|
|
|
|
|
Patients who have undergone sinus intranasal surgery (including polypectomy) within 6 months prior to Visit 1
|
|
|
|
|
Patients who have taken
|
|
|
|
|
Biologic therapy/systemic immunosuppressant to treat inflammatory disease or
|
|
|
|
|
autoimmune disease within 5 half-lives prior to Visit 1
|
|
|
|
|
Any investigational mAb within 5 half-lives prior to Visit 1
|
|
|
|
|
Anti-IgE therapy (omalizumab) within 4 months prior to Visit 1
|
|
|
|
|
Treatment with a live (attenuated) vaccine within 4 weeks prior to Visit 1
|
|
|
|
|
Leukotriene antagonists/modifiers unless patient is on a continuous treatment for at least 30 days prior to Visit 1
|
|
|
|
|
Initiation of allergen immunotherapy within 3 months prior to Visit 1 or a plan to begin therapy or change its dose during the screening or treatment period
|
|
|
|
|
Patients received SCS during screening period (between Visit 1 and Visit 2)
|
|
|
|
|
Either intravenous immunoglobulin therapy and/or plasmapheresis within 30 days prior to Screening Visit (Visit 1)
|
|
|
|
|
The above information is not intended to contain all considerations relevant to a patient's
|
|
|
|
|
potential participation in a clinical trial
|
|
|
|